Abstract
The drug discovery process is complex, time consuming and expensive, and includes preclinical and clinical phases. The pharmaceutical industry is moving from a symptomatic relief focus towards a more pathology-based approach where a better understanding of the pathophysiology should help deliver drugs whose targets are involved in the causative processes underlying the disease. Computational biology and bioinformatics have the potential not only to speed up the drug discovery process, thus reducing the costs, but also to change the way drugs are designed. In this review we focus on the different computational and bioinformatics approaches that have been proposed and applied to the different steps involved in the drug development process. The development of network-reconstruction methods is now making it possible to infer a detailed map of the regulatory circuit among genes, proteins and metabolites. It is likely that the development of these technologies will radically change, in the next decades, the drug discovery process, as we know it today.
Keywords: lead identification, Supervised-learning methods, Leukemia, titration-invariant similarity score (TISS), bioinformatics, reverse engineering
Current Bioinformatics
Title: Computational Biology and Drug Discovery: From Single-Target to Network Drugs
Volume: 1 Issue: 1
Author(s): Alberto Ambesi-Impiombato and Diego d Bernardo
Affiliation:
Keywords: lead identification, Supervised-learning methods, Leukemia, titration-invariant similarity score (TISS), bioinformatics, reverse engineering
Abstract: The drug discovery process is complex, time consuming and expensive, and includes preclinical and clinical phases. The pharmaceutical industry is moving from a symptomatic relief focus towards a more pathology-based approach where a better understanding of the pathophysiology should help deliver drugs whose targets are involved in the causative processes underlying the disease. Computational biology and bioinformatics have the potential not only to speed up the drug discovery process, thus reducing the costs, but also to change the way drugs are designed. In this review we focus on the different computational and bioinformatics approaches that have been proposed and applied to the different steps involved in the drug development process. The development of network-reconstruction methods is now making it possible to infer a detailed map of the regulatory circuit among genes, proteins and metabolites. It is likely that the development of these technologies will radically change, in the next decades, the drug discovery process, as we know it today.
Export Options
About this article
Cite this article as:
Ambesi-Impiombato Alberto and Bernardo d Diego, Computational Biology and Drug Discovery: From Single-Target to Network Drugs, Current Bioinformatics 2006; 1 (1) . https://dx.doi.org/10.2174/157489306775330598
DOI https://dx.doi.org/10.2174/157489306775330598 |
Print ISSN 1574-8936 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-392X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease
Current Hypertension Reviews Recent Advancements in Macrolide Hybrids against <i>Staphylococcus aureus</i>
Current Topics in Medicinal Chemistry Limonin, A Citrus Limonoid, had no Apparent Effect on Cognitive Dysfunction in Mice with Chronic Cerebral Hypoperfusion
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) <i>In silico</i> Mutagenesis and Modeling of Decoy Peptides Targeting CIB1 to Obscure its Role in Triple-negative Breast Cancer Progression
Current Pharmaceutical Design Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-specific Release of Fexofenadine for Ulcerative Colitis
Current Drug Delivery EGFR Inhibitors and Radiation in HNSCC
Current Cancer Therapy Reviews QSAR Investigations on Benzylideneamino and Phenyliminomethyl Scaffolds for Selective COX-2 Inhibition: A Hansch Approach
Medicinal Chemistry Editorial [Hot Topic: Granulocyte Toxicity in the Lung (Guest Editor: Hannu Kankaanranta)]
Current Drug Targets - Inflammation & Allergy Characterization of Mutants of Sulfolobus solfataricus Signature Amidase Able to Hydrolyse R-Ketoprofen Amide
Protein & Peptide Letters Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Drug Delivery Strategies for the Treatment of Helicobacter pylori Infections
Current Pharmaceutical Design Updates on GMSCs Treatment for Autoimmune Diseases
Current Stem Cell Research & Therapy The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug
Current Cancer Drug Targets Detection of Protein-Protein Interactions Using Protein-Fragment Complementation Assays (PCA)
Current Proteomics Current Treatment of HIV Infection
Current Topics in Medicinal Chemistry Liposomal Targeting of Angiogenic Vasculature
Current Drug Delivery Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry An Overview of Chromatographic Analysis of Sulfonamides in Pharmaceutical Preparations and Biological Fluids
Current Pharmaceutical Analysis Natural Products Homoharringtonine and Emetine Alkaloids as SARS-CoV-2 Treatment Options
Current Pharmaceutical Design